Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Aptorum Group Ltd Cl A
(NQ:
APM
)
2.990
+0.110 (+3.82%)
Streaming Delayed Price
Updated: 1:50 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Aptorum Group Ltd Cl A
< Previous
1
2
Next >
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2022
September 30, 2022
From
Aptorum Group Limited
Via
Business Wire
Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
September 23, 2022
Via
ACCESSWIRE
Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in Hong Kong
September 15, 2022
From
Aptorum Group Limited
Via
Business Wire
Aptorum Group Updates on the Clinical Validation of RPIDD Infectious Disease Liquid Biopsy Molecular Diagnostics
September 15, 2022
From
Aptorum Group Limited
Via
Business Wire
Aptorum Group Limited to Present at the H.C. Wainwright Annual Global Investment Conference, September 13-16, 2022
August 25, 2022
From
Aptorum Group Limited
Via
Business Wire
Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
August 19, 2022
Via
ACCESSWIRE
The Global Pharmaceutical Industry is Accelerating; Aptorum Group Has Received Orphan Drug Designation from US FDA for Its SACT-1
July 25, 2022
Via
ACN Newswire
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
Product Safety
Aptorum Group Limited to Present at the H.C. Wainwright Global Investment Conference, May 23 – 26 2022
May 17, 2022
From
Aptorum Group Limited
Via
Business Wire
Aptorum Group Updates on Data from the Completed Phase 1 Clinical Trial of SACT-1, targeting neuroblastoma
May 02, 2022
From
Aptorum Group Limited
Via
Business Wire
Aptorum Group Limited Reports 2021 Fiscal Year End Financial Results and Provides Business Update
April 29, 2022
From
Aptorum Group Limited
Via
Business Wire
First Patent Regarding RPIDD Infectious Disease Liquid Biopsy Technology DNA Library Preparation and Amplification Methods Granted
April 25, 2022
From
Aptorum Group Limited
Via
Business Wire
Aptorum Group Limited Interview to Air on Bloomberg U.S. on the RedChip Money Report®
April 22, 2022
From
Aptorum Group Limited
Via
Business Wire
Aptorum Group Receives FDA Orphan Drug Designation for its SACT-1 Repurposed Drug For The Treatment of Neuroblastoma
January 20, 2022
From
Aptorum Group Limited
Via
Business Wire
Aptorum Group Granted The First Patent for its SACT-1 Repurposed Drug For Treatment of Various Cancer Including but Not Limited to Neuroblastoma
January 18, 2022
From
Aptorum Group Limited
Via
Business Wire
Aptorum Group Announces Updates on the Clinical Validation of its RPIDD Infectious Disease Liquid Biopsy Technology
January 10, 2022
From
Aptorum Group Limited
Via
Business Wire
Aptorum Group Announces the Launch of its Oncology and Autoimmune Discovery and Development Platform Targeting Unmet Mutations and Novel Biomarkers
January 10, 2022
From
Aptorum Group Limited
Via
Business Wire
Aptorum Group Announces Completion of Phase I Clinical Trials for ALS-4 and SACT-1, Small Molecule Drugs Targeted for Infections Caused by Staphylococcus Aureus and Neuroblastoma
January 10, 2022
From
Aptorum Group Limited
Via
Business Wire
Aptorum Group Limited Announces Results of 2021 Annual General Meeting of Shareholders
December 03, 2021
From
Aptorum Group Limited
Via
Business Wire
Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 2, 2021
October 19, 2021
From
Aptorum Group Limited
Via
Business Wire
Aptorum Group Limited Interview to Air on Bloomberg U.S.
October 15, 2021
From
Aptorum Group Limited
Via
Business Wire
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2021
September 15, 2021
From
Aptorum Group Limited
Via
Business Wire
Aptorum Group Limited Has Received IND Clearance From the US FDA to Initiate Clinical Trials for Repurposed Small Molecule Drug SACT-1 for the Treatment of Neuroblastoma
September 15, 2021
From
Aptorum Group Limited
Via
Business Wire
Aptorum Group Announces Further Positive Interim Results of the Phase 1 Clinical Trial of ALS-4 Targeting Staphylococcus aureus
July 12, 2021
From
Aptorum Group Limited
Via
Business Wire
Aptorum Group Interview to Air on Bloomberg Television U.S. on the RedChip Money Report
July 09, 2021
From
Aptorum Group Limited
Via
Business Wire
Aptorum Group CEO Subscribed Shares In The Company
May 26, 2021
From
Aptorum Group Limited
Via
Business Wire
Aptorum Group Announces Positive Interim Phase I Clinical Trial Progress for ALS-4 Targeting Staphylococcus aureus and Positive Pre-IND Progress for SACT-1 Targeting Neuroblastoma
May 24, 2021
From
Aptorum Group Limited
Via
Business Wire
Aptorum Group Limited to Present at The Benzinga Global Small Cap Conference
May 13, 2021
From
Aptorum Group Limited
Via
Business Wire
Aptorum Group Enters into an Agreement with Exeltis to Develop Aptorum’s Novel Preclinical Candidate Targeting Woman’s Gynecological Conditions
May 06, 2021
From
Aptorum Group Limited
Via
Business Wire
Aptorum Group Limited Interview to Air on Bloomberg Television U.S. on the RedChip Money Report
April 23, 2021
From
Aptorum Group Limited
Via
Business Wire
Aptorum Group Enters Into Material Transfer and Exclusive Option-To-License Agreement with Yale University for Its Novel Immunomodulators Potentially Targeting Autoimmune and Oncology Diseases
April 22, 2021
From
Aptorum Group Limited
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.